Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shenzhen (SZSE) — 泰格医药
Other Market Stock Code300347
H-Share Offer PriceHK$ 100.00
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameTigermed
Stock Code03347
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國領先的綜合生物製藥研發服務提供商,提供臨床試驗技術服務及臨床試驗相關服務及實驗室服務,範圍涵蓋藥物和醫療器械的臨床前研究至上市後研究。
Listing Date2020-08-07
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國杭州市濱江區江南大道618號東冠大廈15層
Business Address (Hong Kong)香港灣仔皇后大道東248號陽光中心40樓全層
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitetigermedgrp.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 100.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size100 shares
Entry ThresholdHK$ 10,000
Par ValueRMB 1.0 / shares
Offer Period2020-07-28 to 2020-07-31
Global Offering Shares107,065,100 shares
HK Public Offer Shares (Initial)5,888,600 shares (5.5%)
Public Offer Lots (Initial)58,886lots (Pool A29,443lots,Pool B29,443lots)
International Placing Shares (Initial)101,176,500 shares (94.5%)
Offer Ratio~5.5%
Total Shares Post-IPO856,520,650 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 10,706,510,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 10,000
2 lots 200 HK$ 20,000
3 lots 300 HK$ 30,000
4 lots 400 HK$ 40,000
5 lots 500 HK$ 50,000
6 lots 600 HK$ 60,000
7 lots 700 HK$ 70,000
8 lots 800 HK$ 80,000
9 lots 900 HK$ 90,000
10 lots 1,000 HK$ 100,000
15 lots 1,500 HK$ 150,000
20 lots 2,000 HK$ 200,000
25 lots 2,500 HK$ 250,000
30 lots 3,000 HK$ 300,000
35 lots 3,500 HK$ 350,000
40 lots 4,000 HK$ 400,000
45 lots 4,500 HK$ 450,000
50 lots 5,000 HK$ 500,000
60 lots 6,000 HK$ 600,000
70 lots 7,000 HK$ 700,000
80 lots 8,000 HK$ 800,000
90 lots 9,000 HK$ 900,000
100 lots 10,000 HK$ 1,000,000
200 lots 20,000 HK$ 2,000,000
300 lots 30,000 HK$ 3,000,000
400 lots 40,000 HK$ 4,000,000
500 lots 50,000 HK$ 5,000,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 60,000 HK$ 6,000,000
700 lots 70,000 HK$ 7,000,000
800 lots 80,000 HK$ 8,000,000
900 lots 90,000 HK$ 9,000,000
1,000 lots 100,000 HK$ 10,000,000
2,000 lots 200,000 HK$ 20,000,000
3,000 lots 300,000 HK$ 30,000,000
4,000 lots 400,000 HK$ 40,000,000
5,000 lots 500,000 HK$ 50,000,000
6,000 lots 600,000 HK$ 60,000,000
7,000 lots 700,000 HK$ 70,000,000
8,000 lots 800,000 HK$ 80,000,000
9,000 lots 900,000 HK$ 90,000,000
10,000 lots 1,000,000 HK$ 100,000,000
20,000 lots 2,000,000 HK$ 200,000,000
29,443 lots 2,944,300 HK$ 294,430,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 4.97B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 85,652,065,000
H-Share Market Cap (at Offer Price)HK$ 10,706,510,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣974.9百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201720182019
Revenue 1,682,5042,299,5342,803,309
Cost of sales -969,752-1,318,199-1,511,409
Gross profit 712,752981,3351,291,900
Other income and gains, net 30,91222,23464,149
Selling and distribution expenses -39,749-54,454-81,072
Administrative expenses -239,106-316,423-350,510
Operating profit 504,664772,6691,140,783
Net finance costs -11,661-19,365-42,243
Share of associates and JVs -6,1999,598-9,768
Profit before tax 486,804762,9021,088,772
Income tax expense -92,647-107,653-113,839
Profit for the year 394,157655,249974,933
Profit attributable to owners 344,977576,886841,247
Balance Sheet
Item 2017201820192020-03
Cash and cash equivalents 145191,206
Trade and bills receivables 468,584533,811756,028
Inventories 299,488382,695490,393
Total current assets 1,377,2811,648,7403,366,314
Total assets 3,733,0744,586,6047,567,976
Total current liabilities 786,7301,259,9801,811,986
Total liabilities 844,5261,314,4552,046,698
Total equity 2,888,5483,272,1495,521,278
Equity attributable to owners 2,555,6192,828,0424,246,842
Interest-bearing borrowings 276,868634,863901,3631,121,629
Cash Flow Statement
Item 2017201820192020-03
Net cash from operating activities 308,347509,373537,551
Depreciation of PP&E 27,46955,64850,27312,134
Depreciation of right-of-use assets 46,56214,454
Amortisation of intangible assets 4,7515,4927,3674,395
Purchase of PP&E -49,293-75,815-88,600-20,328
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 113.3
First Day OpenHK$ 119.0
First Day Change13.30%
First Day Volume33927600.0
First Day Turnover3926800000.0
Use of Proceeds
1、15%或約1,540.9百萬港元用于內生擴大及提升我們在臨床試驗技術服務及臨床試驗相關服務種類及能力,以滿足海外市場對我們服務不斷增加的需求; 2、40%或約4,109.0百萬港元用于作為我們全球擴張計劃的一部分,為潛在收購可補足我們現有業務的具吸引力海外臨床合同研究機構提供資金; 3、20%或約2,054.5百萬港元用于內生通過對以創新業務模式營運及具增長潛力的公司進行少數股權投資,促進我們生物制藥研發生態系統發展; 4、10%或約1,027.3百萬港元用于償還我們截至2020年5月31日的若干未償還借款; 5、5%或約513.6百萬港元用于開發及推行技術以進一步提升我們綜合服務種類的質素及效率; 6、10%或約1,027.3百萬港元用于營運資金及一般企業用途。

Underwriting Syndicate

Joint Sponsors (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198 海通国际资本有限公司 CE ADQ859 中信证券(香港)有限公司 CE AAK249 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (6)
Merrill Lynch (Asia Pacific) Limited CE AAC198 海通国际证券有限公司 CE AAF806 CLSA LIMITED CE AAB893 中国国际金融香港证券有限公司 CE AEN894 UBS Securities Hong Kong Limited CE BIN466 Jefferies Hong Kong Limited CE ATS546
Joint Bookrunners (11)
Merrill Lynch (Asia Pacific) Limited CE AAC198 海通国际证券有限公司 CE AAF806 中信证券(香港)有限公司 CE AAK249 中国国际金融香港证券有限公司 CE AEN894 UBS Securities Hong Kong Limited CE BIN466 Jefferies Hong Kong Limited CE ATS546 招银国际融资有限公司 CE AVM940 Credit Suisse (Hong Kong) Limited CE AAO017 Fosun International Securities Limited CE AAF432 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362
Joint Lead Managers (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198 海通国际证券有限公司 CE AAF806 中信证券(香港)有限公司 CE AAK249 中国国际金融香港证券有限公司 CE AEN894

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman葉小平—
Company Secretary高峻—
No director data available.

Major Shareholders

Major Shareholders & Holdings葉小平博士及曹曉春女士(一致行動人)合共持有本公司已發行股份總數約31.3%(全球發售完成後約27.4%),為控股股東。
About this page

This page shows Tigermed (03347) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect